| Issue |
BIO Web Conf.
Volume 86, 2024
International Conference on Recent Trends in Biomedical Sciences (RTBS-2023)
|
|
|---|---|---|
| Article Number | 01038 | |
| Number of page(s) | 7 | |
| DOI | https://doi.org/10.1051/bioconf/20248601038 | |
| Published online | 12 January 2024 | |
OTX015 PROTACs: Emerging Novel Therapeutic Agents in Cancer Treatment
1 Chitkara College of Pharmacy, Chitkara University, Punjab, 140401 - India
2 Lambton College, Toronto
3 Department of Pharmaceutical, Ministry of Chemicals &Fertilisers, GoI, New Delhi - 110001
4 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab - 144411
* Corresponding author: rajwinder.kaur@chitkara.edu.in, sanjeev.24026@lpu.co.in
Cancer is a wide-spreading disease. Its count goes on increasing and became the second leading cause of death in respect of diseases. New cancer-targeting molecules are explored. In this study, we tried to collect information about one such molecule, OTX015. Articles were searched across reputed search engines and publishers such as Cochrane, EMBASE, The Lancet, PubMed, GoogleScholar, ScienceDirect, Wiley Online, Springer and Bentham Science by using different keywords: “OTX015”, “Cancer”, “Small molecule PROTACs”, “BRD/BET” and “BET inhibitors”. The quality papers were retrieved, studied, categorized into different sections, analyzed, and used for article writing.OTX015 is a novel molecule in clinical trials. It showed some promising results in various cancers as well as other diseases like latent-HIV with the least side-effects.This article will give an insight into Small Molecules as PROTACs, their advantages and disadvantages, OTX015 and its PROTAC ARV- 825. It is advised that more research/studies are required to be carried out to know more about OTX015 and other PROTACs, their advancements, receptors, and mechanism/ mode of action to know their abilities to work against proteins involving diseases.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.